Desloratadine
- Generic Name
- Desloratadine
- Brand Names
- Aerius, Clarinex, Clarinex-D, Neoclarityn, Desloratadine ratiopharm, Desloratadine Teva, Desloratadine Actavis, Dasselta, Azomyr
- Drug Type
- Small Molecule
- Chemical Formula
- C19H19ClN2
- CAS Number
- 100643-71-8
- Unique Ingredient Identifier
- FVF865388R
- Background
Desloratadine is a second generation, tricyclic antihistamine that which has a selective and peripheral H1-antagonist action. It is the active descarboethoxy metabolite of loratidine (a second generation histamine). Desloratidine has a long-lasting effect and does not cause drowsiness because it does not readily enter the central nervous system.
- Indication
For the relief of symptoms of seasonal allergic rhinitis, perennial (non-seasonal) allergic rhinitis. Desloratidine is also used for the sympomatic treatment of pruritus and urticaria (hives) associated with chronic idiopathic urticaria.
- Associated Conditions
- Allergic Rhinitis (AR), Asthma, Chronic Idiopathic Urticaria, Common Cold, Nasal Congestion, Perennial Allergic Rhinitis (PAR), Seasonal Allergic Rhinitis, Nasal symptoms, Non-nasal symptoms
- Associated Therapies
- Antihistamine
An Open-Label Study of the Effects of Desloratadine (Aerius.) Treatment on the Quality of Life of Patients With Chronic Idiopathic Urticaria (Study P02540)
- First Posted Date
- 2008-11-21
- Last Posted Date
- 2022-02-17
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 51
- Registration Number
- NCT00795522
The Effect of Desloratadine and Levocetirizine on Nasal Obstruction (Study P03609)
- First Posted Date
- 2008-11-11
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 81
- Registration Number
- NCT00789152
Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. vs. Placebo for Treating Seasonal Allergic Rhinitis (SAR)(Study P04053)(COMPLETED)
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 722
- Registration Number
- NCT00783211
Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. vs. Placebo for Treating Seasonal Allergic Rhinitis (SAR) (Study P04054)
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 728
- Registration Number
- NCT00783146
A Comparison of Aerius Continuous Treatment Versus Aerius PRN for Chronic Idiopathic Urticaria (Study P03147)
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 129
- Registration Number
- NCT00783354
Multi-Center, Pediatric, Open-Label, Preference Study of Desloratadine 2.5 mg Reditab (SCH34117) and Zyrtec ® 5.0 mg Chewable Tablet Medications (Study P04573) (Completed)
- First Posted Date
- 2008-10-27
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 220
- Registration Number
- NCT00780403
Multi-center, Pediatric, Open-label, Preference Study of Desloratadine 2.5 mg Reditab (SCH34117) and Zyrtec 5.0 mg Chewable Tablet Medications (Study P04574)(COMPLETED)
- First Posted Date
- 2008-10-24
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 217
- Registration Number
- NCT00779116
Effectiveness and Safety of Desloratadine in Patients With Allergic Airway Disease During the Pollen Season (Study P03284)
- First Posted Date
- 2008-10-24
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 506
- Registration Number
- NCT00779636
Safety of Desloratadine in Children With Allergy Sensitivity and Chronic Hives, Who Are Poor Metabolizers of Desloratadine (Study P02994)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-09-23
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 97
- Registration Number
- NCT00757562
A Comparative Double-blind, Double-dummy Study of Desloratadine (DL) 5 mg Once Daily, Cetirizine 10 mg Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (Study P03736)
- First Posted Date
- 2008-09-11
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 149
- Registration Number
- NCT00751166
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath